Findings from a head-to-head study conducted by US pharma Merck & Co (NYSE: MRK) have shown almost complete efficacy of elbasvir/grazoprevir in the treatment of chronic hepatitis C.
A Phase III trial compared the combination to a regimen of sofosbuvir tablets plus peginterferon and ribavirin in both treatment-naïve and treatment-experienced patients with chronic hepatitis C (HCV) genotype 1 or 4 infection.
The efficacy endpoint of sustained virologic response (SVR) 12 weeks after the completion of therapy, SVR12 – considered virologic cure – was achieved in 128 out of 129 of patients receiving elbasvir/grazoprevir for 12 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze